Milestone Milestone

Milestone

  • 2027

    2026
    ✦ Established the Smart Healthcare Division to develop products
     and services centered on "sovereign AI" for the healthcare
     sector.
    ✦ Formed a strategic alliance with APMIC (Accelerate Private
     Machine Intelligence Company) to expand sovereign AI
     initiatives in healthcare across Taiwan and Asia.
    ✦ Developed OEM services for AI-powered medical devices
     and applications utilizing AI agents in healthcare.
    ✦ Collaborated with a medical center in Taiwan to co-develop
     the first sovereign AI large language model (LLM) for
     healthcare.
    ✦ Completed a private placement of common shares totaling
     NT$30 million; paid-in capital increased to NT$216.003
     million.
    ✦ Completed a private placement of common shares totaling
     NT$20 million, alongside the exercise of employee stock
     options totaling NT$1.58 million; paid-in capital reached
     NT$237.583 million.
    ✦ Completed a private placement of common shares totaling
     NT$34.2 million, alongside the exercise of employee stock
     options totaling NT$5.64 million; paid-in capital reached
     NT$277.423 million.

  • 2026

    2025
    ✦ Completed a cash capital increase of NT$10 million, bringing
     the paid-in capital to NT$161.003 million.
    ✦ Completed a private placement of common shares totaling
     NT$25 million, bringing the paid-in capital to NT$186.003
     million.
    ✦ Acquired a 16.22% equity stake in the UK-based company
     Adtec Healthcare Limited (AHL).
    ✦ Initiated the certification process for medical cold plasma
     devices across six Southeast Asian countries.
    ✦ Launched a commercialization plan for medical cold plasma
     in the Taiwan market, securing entry into nine major medical
     centers.
    ✦ Obtained a medical device code for self-pay (out-of-pocket)
     use from the Kaohsiung City Public Health Bureau for medical
     cold plasma devices intended for the treatment of chronic
     wounds.

  • 2025

    2024
    ✦ Introduced medical low-temperature plasma devices for chronic
     wound treatment into major medical centers in Taiwan.
    ✦ Initiated the certification process for medical low-temperature
     plasma chronic wound treatment devices in Southeast Asian
     markets.
    ✦ Partnered with National Taiwan University Hospital (NTUH) to
     develop innovative bioabsorbable middle-ear ventilation tubes.
    ✦ Began preparations for establishing an Asian manufacturing
     facility for medical low-temperature plasma chronic wound
     treatment devices.
    ✦ Completed a cash capital increase of NT$8 million, bringing
     the total paid-in capital to NT$151.003 million.

  • 2024

    2023
    ✦ Expansion of the market presence for medical cold-plasma
     devices for chronic wound treatment into Asia.
    ✦ Medical cold-plasma device for chronic wound treatment
     receives the first product certification of its kind in Asia
     (TFDA approval).
    ✦ Bioresorbable magnesium-based stent project, in collaboration
     with National Taiwan University Hospital (NTUH), secures a
     grant under the Ministry of Science and Technology's industry
     -academia cooperation program.

  • 2023

    2022
    ✦ Completed a cash capital increase of NT$4.9 million, bringing
     the total paid-in capital to NT$1430.03 million.
    ✦ Signed a memorandum of understanding (MOU) for strategic
     collaboration on clinical trials for an innovative stent with NTU
     Hospital Hsin-Chu Branch (National Taiwan University Hospital
     Biomedical Park Branch).
    ✦ Began public demonstrations of the medical cold-plasma
     device for chronic wound treatment in the Taiwan market.

  • 2022

    2021
    ✦ Completed a cash capital increase of NT$15 million, bringing
     the total paid-in capital to NT$138.103 million.
    ✦ Partnered with the UK-based Adtec Europe Limited (AEL) on
     the first application of a medical low-temperature plasma
     system for the treatment of chronic wounds.
    ✦ Collaborated with National Taiwan University Hospital and the
     University of Tokyo on a novel stent system designed
     specifically for the treatment of dialysis-related vascular
     access.

  • 2021

    2020
    ✦ Innovative plasma-based epidemic prevention and sterilization
     equipment recognized as one of the "Top 50 Innovative
     Technologies for Epidemic Prevention in Taiwan."
    ✦ Developed bioresorbable vascular stent technology specifically
     for dialysis.
    ✦ Completed an "A+" advanced technology development project
     focused on bioresorbable vascular stents.
    ✦ Initiated the development and product certification process for
     advanced medical low-temperature plasma wound-healing
     technology.
    ✦ Raised NT$9.375 million through a private placement of Class
     A preferred shares, bringing the total paid-in capital to
     NT$123.103 million.

  • 2020

    2019
    ✦ Bioresorbable vascular stent technology has entered the animal
     testing and validation phase.
    ✦ Surface treatment technology has been introduced for client
     product validation in proton exchange membranes (PEMs) for
     electric vehicle fuel cells.
    ✦ Bioresorbable stent technology received the "16th National
     Innovation Award."
    ✦ Developed a "portable plasma-based anti-epidemic sterilization
     and care device."
    ✦ Recognized by Deloitte as one of the "Technology Fast 500"
     high-growth companies.
    ✦ Completed a cash capital increase of NT$2.75 million, bringing
     the total paid-in capital to NT$113.728 million.

  • 2019

    2018
    ✦ Completed the development of a patented atmospheric
     -pressure plasma coating technology and initiated customer
     validation for its application in the surface modification of
     next-generation intraocular lens (IOL) medical devices.

  • 2018

    2017
    ✦ Approved by the Taipei Exchange (TPEx) as a "publicly issued
     company."
    ✦ Certified by the Industrial Development Bureau of the Ministry
     of Economic Affairs as a "biotech and new drug company."
    ✦ Awarded a grant under the Ministry of Economic Affairs' "A+
     Forward-looking Technology R&D Program" to develop the first
     domestically produced bioresorbable vascular scaffold and its
     associated technology.
    ✦ Completed a cash capital increase of NT$14.2 million, bringing
     the total paid-in capital to NT$110.978 million.

  • 2017

    2016
    ✦ Developed low-temperature, non-contact plasma modification
     equipment and introduced it to a major Asian manufacturer of
     intraocular lenses; collaborated on the development of new
     surface modification technology for orthokeratology (corneal
     reshaping) lenses.
    ✦ Introduced plasma modification equipment into the domestic
     functional textile industry.
    ✦ Partnered with domestic industry, academia, and the medical
     sector to develop a new generation of bioresorbable vascular
     stent technology, entering the field of medical devices for
     peripheral and cardiovascular interventional procedures.
    ✦ Completed a cash capital increase and the exercise of
     employee stock options totaling NT$2.158 million, bringing
     the paid-in capital to NT$96.778 million.

  • 2016

    2015
    ✦ Selected as a featured vendor to showcase achievements under
     the Ministry of Education's "Aim for the Top University Plan."
    ✦ Entered the domestic contact lens surface modification market
     and expanded into the broader ophthalmic medical device
     surface modification sector.
    ✦ Commenced sales of low-temperature, non-contact plasma
     surface modification equipment for use in high-end functional
     textiles.
    ✦ Partnered with a domestic manufacturer of neural repair
     medical devices to develop bioabsorbable nerve conduit
     technology.
    ✦ Established a medical device facility in Hsinchu, serving as a
     key hub for the R&D and production of medical devices.
    ✦ Obtained a factory registration certificate.
    ✦ Secured a manufacturing-based pharmaceutical business
     license.
    ✦ Completed a capital increase via cash issuance and the
     exercise of employee stock options, totaling NT$13.82
     million; post-increase paid-in capital reached NT$94.62
     million.

  • 2015

    2014
    ✦ Selected for the "Emerging Industry Acceleration and Incubation
     Program" (Biotechnology Track) by the Small and Medium
     Enterprise Administration of the Ministry of Economic Affairs
     in 2014.
    ✦ The first enterprise in Taiwan to receive full-amount funding
     from the National Development Fund's Angel Investment
     Program.
    ✦ Completed successive cash capital increases totaling NT$42.8
     million, bringing the paid-in capital to NT$80.8 million.

  • 2014

    2013
    ✦ In April 2013, SG Biomedical Co., Ltd. was established with a
     paid-in capital of NT$15 million.
    ✦ Formed a strategic partnership with N2 Biomedical, LLC (USA)
     regarding surface treatment technologies for high-end medical
     devices.
    ✦ Established operations within the National Tsing Hua University
     Incubation Center.
    ✦ Completed subsequent cash capital increases totaling NT$22
     million, bringing the total paid-in capital to NT$38 million.

Go To Top